由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
_pennystock版 - ANX快上
相关主题
明天 ANX是升还是降CEU
Rodman & Renshaw Annual Global Investment Conference, 05/1FDA Drug Approvals in 2011
EPCT 蓄势待发【转留园陈观西】Biotech Calendar: FDA Drug Approvals in 2011 (ZT from AF)
RODM 汇总贴 讨论Re此帖Biotech Calendar: 2011 FDA Drug Approvals
Rodman & Renshaw Annual China Investment ConferenceOREX panel today
Rodman & Renshaw 6th Annual Global Healthcare Conferencemnkd delayed FDA decision
骡马大会KV/A cut MAKENA PRICE by 55% 利好还是利多?
12/23/2011 大盘BMTI
相关话题的讨论汇总
话题: adventrx话题: drug话题: fda话题: anx话题: treatment
1 (共1页)
t**u
发帖数: 1572
1
Rodman & Renshaw raised Adventrx's price target to $16,
S***7
发帖数: 657
2
It seems you like to recommend picks but never give reasons. Can you give
more info?
t**u
发帖数: 1572
3
Rodman & Renshaw raised Adventrx's price target to $16,

【在 S***7 的大作中提到】
: It seems you like to recommend picks but never give reasons. Can you give
: more info?

a****c
发帖数: 339
4
In my limited experience, this kind of price target never materialize. This
kind of news always lags behind.
s**********9
发帖数: 846
5
5+?
w*********7
发帖数: 2883
6
$1.05了
L*******B
发帖数: 837
7
Adventrx: FDA Rejects New Drug Application For Lung Cancer Treatment
Adventrx: FDA Rejects New Drug Application For Lung Cancer Treatment
DOW JONES NEWSWIRES
Adventrx Pharmaceuticals Inc. (ANX) said the U.S. Food and Drug
Administration couldn't approve its new drug application for lung-cancer
treatment Exelbine.
Shares in the development-stage drug maker plunged 61%, to 99 cents after
hours, on the news. Through the close, the stock had been up 25% over the
last year, better than the broader market.
The company said it was disappointed by the decision about the treatment for
nonsmall-cell lung cancer, adding that it wasn't in good position to
comment on the future of the Exelbine program until it has a chance to meet
with the FDA. It plans to request a type-A meeting--which is designed to
resolve an issue with an otherwise stalled product--next week. Type-A
meetings are meant to be scheduled within 30 days of such a request.
"In the meantime, our resources and focus are on ANX-188 and ANX-514, which
we believe are the long-term value drivers for our company," Chief Executive
Brian M. Culley said. He was referring to a drug for sickle-cell crisis and
a reformation of the Taxotere cancer treatment, respectively.
In its complete response letter, the FDA said the authenticity of drug
products used in a trial couldn't be verified, which threw the trial's
results into question. Adventrx must repeat the bioequivalence trial, the
FDA said in the letter.
The company said it believes the authenticity of the drug products used in
the pivotal study is verifiable.
The letter also requested information about product quality.
1 (共1页)
相关主题
BMTIRodman & Renshaw Annual China Investment Conference
UPDATE 1-US FDA panel rejects Jazz drug for fibromyalgiaRodman & Renshaw 6th Annual Global Healthcare Conference
Amylin, Lilly, Alkermes Shares Slump as FDA Rejects Bydureon Diabetes Drug骡马大会
OREX, another vicl?12/23/2011 大盘
明天 ANX是升还是降CEU
Rodman & Renshaw Annual Global Investment Conference, 05/1FDA Drug Approvals in 2011
EPCT 蓄势待发【转留园陈观西】Biotech Calendar: FDA Drug Approvals in 2011 (ZT from AF)
RODM 汇总贴 讨论Re此帖Biotech Calendar: 2011 FDA Drug Approvals
相关话题的讨论汇总
话题: adventrx话题: drug话题: fda话题: anx话题: treatment